|
||
© The Rockefeller University Press,
0021-9525/2000//791 $5.00
The Journal of Cell Biology, Volume 148, Number 4,
, 2000 791-800
Original Article |
Oncogenic Raf-1 Disrupts Epithelial Tight Junctions via Downregulation of Occludin
mrsny{at}gene.com
Occludin is an integral membrane protein of the epithelial cell tight junction (TJ). Its potential role in coordinating structural and functional events of TJ formation has been suggested recently. Using a rat salivary gland epithelial cell line (Pa-4) as a model system, we have demonstrated that occludin not only is a critical component of functional TJs but also controls the phenotypic changes associated with epithelium oncogenesis. Transfection of an oncogenic Raf-1 into Pa-4 cells resulted in a complete loss of TJ function and the acquisition of a stratified phenotype that lacked cell–cell contact growth control. The expression of occludin and claudin-1 was downregulated, and the distribution patterns of ZO-1 and E-cadherin were altered. Introduction of the human occludin gene into Raf-1–activated Pa-4 cells resulted in reacquisition of a monolayer phenotype and the formation of functionally intact TJs. In addition, the presence of exogenous occludin protein led to a recovery in claudin-1 protein level, relocation of the zonula occludens 1 protein (ZO-1) to the TJ, and redistribution of E-cadherin to the lateral membrane. Furthermore, the expression of occludin inhibited anchorage-independent growth of Raf-1–activated Pa-4 cells in soft agarose. Thus, occludin may act as a pivotal signaling molecule in oncogenic Raf- 1–induced disruption of TJs, and regulates phenotypic changes associated with epithelial cell transformation.
Key Words: occludin Raf-MEK-ERK signaling tight junction claudin-1 epithelium transformation
© 2000 The Rockefeller University Press
| Introduction |
|---|
|
|
|---|
Loss of TJ and AJ structures is frequently observed in epithelium-derived cancers (Quinonez and Simon 1988). E-cadherin at AJ complexes signals through interactions involving
-, β-, and
-catenins (Weiss et al. 1998) and loss of functional coupling through E-cadherin has been shown to induce a transformed phenotype in epithelial cells (Takeichi 1993). Although epithelial-derived cancers appear to be lacking both AJ and TJ complexes (Quinonez and Simon 1988), a role for functional coupling through TJ structures similar to that observed through AJ structures has not been described. It is possible that antineoplastic signaling through TJ structures is similar to that observed for AJ structures. This is supported by the finding that several tumor-promoting agents can induce TJ disruption (Soler et al. 1993), and that neoplastic progression can be correlated with an increase in paracellular permeability across epithelia, suggesting a loss of TJ function (Mullin et al. 1997). If signaling through cell–cell contacts at AJ and TJ structures is important for growth and differentiation events in epithelial cells, then similar mechanisms may control the activity of these two systems.
Sequence mutations that result in a constitutively active state of the small GTP-binding protein Ras are commonly associated with epithelium oncogenesis (Yuspa and Poirier 1988). Also, the cell activation characteristics of ras mutations make it an important component in the cascade of genetic alterations described for cancers derived from epithelial cell sheets (Vogelstein et al. 1988). Thus, Ras and the intracellular pathways driven by Ras would be prime candidates for possible regulatory function if TJ signaling was a component of epithelial cell transformation. Activated Ras stimulates multiple intracellular signaling pathways (Marshall 1996). In particular, Raf-1 is considered to be a primary and central downstream effector of Ras (Marshall 1996). A well-established signaling pathway activated by Raf-1 involves sequential phosphorylation and activation of mitogen-activated protein kinase (MEK) and extracellular-regulated kinase (ERK) kinases (Cobb et al. 1994). Activated ERK kinases regulate a variety of cellular processes, including proliferation, differentiation, and transformation (Cobb et al. 1994). We manipulated the activity of Raf-1 in Pa-4 cells, an immortalized rat parotid gland cell line, which grows as a monolayer with high TEER on semipermeable filter supports similar to normal epithelia. Stable transfections of Pa-4 cells were carried out with an oncogenic Raf-1,
Raf-1:ER, which was constructed by fusing the kinase domain of Raf-1 with the hormone-binding domain of estrogen receptor (Samuels et al. 1993). We have shown that a constitutively active Raf-1 induces the transition of Pa-4 cells from a high-resistance monolayer to a low-resistance multilayer phenotype characteristic of oncogenic conversion. These modified cells demonstrate a redistribution of the actin cytoskeleton along with a downregulation of occludin expression. In addition, introduction of an exogenous occludin gene into Raf-1–activated Pa-4 cells resulted in reacquisition of normal epithelial monolayer phenotype and functionally intact TJs. Furthermore, the expression of exogenous occludin appeared to stabilize and coordinate membrane localization of other junctional proteins in Raf-1–activated Pa-4 cells, and the presence of occludin also inhibited anchorage-independent growth of Pa-4
Raf:ER cells. Based on these results, we suggest that occludin plays a critical role in the disruption of epithelial TJs induced by oncogenic Raf-1.
| Materials and Methods |
|---|
|
|
|---|
Constructs and Plasmids
A constitutively active Raf-1 (
Raf-1:ER), comprised of the catalytic domain of human Raf-1 fused with the hormone-binding domain of human estrogen receptor was constructed as described (Samuels et al. 1993). An active ras plasmid, c-Ki-ras2, was kindly provided by Dr. David Goeddel, Genentech Inc., South San Francisco, CA (Capon et al. 1983). Raf BXB, a constitutively active form of Raf-1 containing only the catalytic domain of the kinase, was kindly provided by Dr. Jakob Troppmair, University of Wurzburg, Wurzburg, Germany (Bruder et al. 1992). An active MEK mutant, pFC-MEK1, was obtained from Stratagene. Human occludin cDNA was cloned using a T84 cell library (Stratagene). The probe used in cloning and Northern blotting was obtained by reverse transcription–PCR. Human occludin cDNA was then subcloned into pCB6 vector, which has a cytomegalovirus promotor.
Cell Culture, Transfections, and Treatments
Pa-4
Raf-1:ER cells were established as described previously by stably transfecting Pa-4 cells with the
Raf-1:ER construct (Li et al. 1997). Pa-4-vec and Pa-4
Raf-1:ER cells were cultured in DMEM/F12 (1:1) medium supplemented with 2.5% FBS, insulin (5 µg/ml), transferrin (5 µg/ml), EGF (25 ng/ml), hydrocortisone (1.1 µM), glutamate (5 mM), G418 (600 µg/ml), and were maintained in a humidified atmosphere containing 5% CO2 and 95% air at 35°C. Pa-4
Raf-1:ER-occludin cells were raised by stably transfecting Pa-4
Raf-1:ER cells with pCB6-occludin and pTK-Hyg vector (Clontech) for hygromycin selection (100 µg/ml). Charcoal-stripped serum was used in maintaining Pa-4
Raf-1:ER and Pa-4
Raf-1:ER-occludin cells to minimize the estrogen level in the culture medium. Cells grown on semipermeable supports were plated at 106 cells/cm2 onto collagen-coated clear polyester membrane of Costar Transwell® (0.4-µm pore size, 1-cm2 surface area). The transepithelial resistance of confluent epithelial sheets was measured after 1 wk in culture with a chopstick Millicell-ERS® voltmeter (Millipore). Transient transfections were performed using Lipofectamine PlusTM (Life Technologies, Inc.) and following the manufacturer's protocol. Cells were collected and lysed 48 h after the start of transfection. Treatment of PD98059 in the transient transfection experiments was carried out by adding the inhibitor (20 µM final) 5 h after the start of transfection. Medium was replaced every 24 h with fresh PD98059.
Western and Northern Blottings
Western Blotting.
Cell lysates, prepared as Triton X-100–soluble and –insoluble fractions, were made as described previously (Li et al. 1997). In brief, cells were lysed in gold lysis buffer (Samuels et al. 1993) containing 20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 5 mM EDTA, 10% (vol/vol) glycerol, 1% (vol/vol) Triton X-100, 1 mM PMSF, 1 mM aprotinin, 1 mM leupeptin, 1 µM pepstatin A, 1 mM sodium orthovanadate, 1 mM EGTA, 10 mM NaF, 1 mM tetrasodium pyrophosphate, 100 µM β-glycerophosphate at 4°C. Lysates were incubated at 4°C for 10 min, and the insoluble material was removed by centrifugation at 12,000 g for 10 min at 4°C. Triton X-100–insoluble pellets were dissolved in RIPA buffer containing 0.2% SDS. Protein concentrations were determined by Pierce BCA assay. Equal amounts of protein of cellular lysates (20 µg) were subjected to SDS-PAGE. After electrophoresis, proteins were electroblotted onto PVDF membranes (Bio-Rad Laboratories). Membranes were blocked with 5% milk solution for 1 h before incubation with primary antibodies. HRP-conjugated secondary antibodies and the enhanced chemiluminescence detection system (NENTM Life Science Products, Inc.) were used to detect bound antibodies. The quantitative analyses of protein levels were carried out using the NIH Image 1.60/PPC software.
Northern Blotting.
Total cellular RNA was prepared using TRIzolTM reagent according to the manufacturer's instructions (Life Technologies). Denatured samples were size fractionated on a formaldehyde (2.2 M)/agarose (1.5%) gel, blotted onto a ZetaProbe nylon membrane (Bio-Rad Laboratories) and hybridized with a 32P-labeled DNA probe prepared using the Ready-To-Go DNA labeling kit (Amersham Pharmacia Biotech). Northern analysis for claudin-1 message levels was carried out using a PCR-derived cDNA sequence probe (Furuse et al., 1998). Glyceraldehyde 3-phosphate dehydrogenase mRNA levels were monitored as loading controls.
Microscopy and Confocal Imaging
Phase-contrast microscopy of cells on plastic culture dishes was done using a Nikon Diaphot 300 inverted microscope attached to a Nikon N6006 camera. Cells grown on Transwell® filters were fixed in 10% normal buffered formalin. Thin sections cut from paraffin-embedded samples were stained with hematoxylin and eosin and viewed by light microscopy. Characterization of filamentous actin distribution was achieved using cells fixed in formalin, permeabilized with 0.2% (vol/vol) Triton X-100, and labeled with rhodamine-phalloidin as described previously (Phillips and Tsan 1988). Immunofluorescence staining of occludin, ZO-1, E-cadherin, and claudin-1 was carried out on cells fixed in methanol at –20°C for 10 min. Cells were then analyzed using a Leica TCS SP laser scanning confocal microscope.
Measurement of Cloning Efficiency in Soft Agarose
Pa-4-vec, Pa-4
Raf-1:ER, and Pa-4
Raf-1:ER-occludin cells were plated at 10,000 cells per 35-mm culture dish in 1 ml of 0.35% (wt/vol) low melting temperature (LMT) agarose solution diluted with medium in the absence or presence of 1 µM estradiol. The dishes were coated with 1 ml of 0.7% (wt/vol) LMT agarose before cell plating, and 1 ml of overlay medium was added after cell plating. The overlay medium was changed every 3 d and fresh estradiol was added. After 15 d, the cells were stained with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; 0.05 mg/ml). The stained plates were photographed, and colonies >0.4 mm in diameter were counted and analyzed.
| Results |
|---|
|
|
|---|
Raf-1:ER protein and activation of the Raf-MEK-ERK kinase pathway in the stably transfected cells, Pa-4
Raf-1:ER, have been characterized previously (Li et al. 1997). Here, we verified an increased Raf-1 activity in Pa-4
Raf-1:ER cells by measuring the phosphorylation levels of ERK1 and ERK2 (Fig. 1 A). When grown on plastic, Pa-4
Raf-1:ER cells displayed significant morphological changes compared with vector-transfected control cells (Pa-4-vec) (Fig. 1 B), and had prominent stress fibers instead of pericellular actin rings (Fig. 1 C). When cultured on semipermeable filter supports, Pa-4
Raf-1:ER cells lost their ability to form high-resistance monolayers and acquired a stratified, low-resistance phenotype (Fig. 1 D). Immunofluorescence staining of occludin showed normal peripheral distribution pattern in control cells, but there was only background staining of occludin in Pa-4
Raf-1:ER cells (Fig. 1 E). Western analyses revealed that Pa-4-vec cells had high levels of occludin protein in both Triton X-100–soluble and –insoluble lysates (Fig. 1 F). In the Triton X-100–insoluble fraction, where cytoskeleton-associated proteins are enriched (Wong 1997), a large percentage of occludin was hyperphosphorylated and probably represented a functional component of the TJ (Fig. 1 F). By comparison, Pa-4
Raf-1:ER cells completely lost their expression of occludin (Fig. 1 F, arrow). Northern analysis demonstrated that the downregulation of occludin protein in Pa-4
Raf-1:ER cells correlated with a complete loss of occludin mRNA (Fig. 1 G).
|
|
Raf-1:ER Cells Resulted in Reacquisition of Normal Epithelial Phenotype and Functionally Intact TJs
Raf-1:ER cells, which no longer express endogenous occludin. A total of eight Pa-4
Raf-1:ER-occludin cell clones were isolated and analyzed. Data from a representative clone, clone No. 2, have been presented for most studies. Control transfections with pCB6 vector alone did not yield any clones distinguishable from Pa-4
Raf-1:ER cells. Occludin-transfected Pa-4
Raf-1:ER cells were verified to have similar levels of
Raf-1:ER protein and phosphorylated ERK1 and ERK2 compared with Pa-4
Raf-1:ER cells (Fig. 3 A), indicating that elevated activity of the Raf-MEK-ERK kinase pathway was maintained. Immunoblotting of protein lysates of Pa-4
Raf-1:ER-occludin cells confirmed the presence of occludin in both Triton X-100–soluble and –insoluble fractions (Fig. 3 B), and hyperphosphorylated occludin in the Triton X-100–insoluble fraction only (Fig. 3 B, arrow). Immunostaining of Pa-4
Raf-1:ER-occludin cells verified the normal distribution of occludin at the periphery of cells (Fig. 3 C). To demonstrate that the occludin protein detected was exogenous, PCR primers were designed using unique sequences in the 5'-untranslated regions of rat and human occludin cDNAs. Reverse transcription–PCR results revealed that rat occludin mRNA was only present in Pa-4-vec cells, whereas human occludin mRNA was only detectable in Pa-4
Raf-1:ER-occludin cells (Fig. 3 D). When cultured on plastic, Pa-4
Raf-1:ER-occludin cells displayed morphology indistinguishable from that of Pa-4-vec cells (Fig. 3 E), and had similar annular rings of actin (Fig. 3 F). When cultured on semipermeable filter supports, Pa-4
Raf-1:ER-occludin cells formed monolayers (Fig. 3 G) with TEER values of
900
·cm2 (Fig. 3 H), demonstrating the assembly of functional TJs. It is not surprising that the TEER of Pa-4
Raf-1:ER-occludin cells did not recover fully to control levels, because these cells still have elevated Raf-1 activity, which is likely to affect other components responsible for the fine-tuning of epithelial TJs. Another possible reason is that human occludin protein may not work perfectly in a rat cell line. But our results clearly demonstrated that occludin played a crucial role in oncogenic Raf-1–induced disruption of epithelial TJs.
|
Raf-1:ER cells. Although ZO-1 protein was no longer exclusively located at the cell–cell contact points in Pa-4
Raf-1:ER cells, there was still a substantial amount of ZO-1 appearing as plaques along the cell border, suggesting its membrane localization is independent of occludin expression and functional TJs. Introduction of exogenous occludin restored the distribution patterns of these two proteins to those observed in control cells (Fig. 4A and Fig. B). Raf-1 activation did not significantly affect the overall protein level of ZO-1, but slightly reduced the ZO-1 level in Triton X-100–insoluble fractions. The level of Triton X-100–insoluble ZO-1 recovered after introduction of occludin (Fig. 4 C). This is consistent with our immunofluorescence results, where we observed a decrease in ZO-1 levels at the lateral membrane in Pa-4
Raf-1:ER cells, and a reconcentration at the TJs in Pa-4
Raf-1:ER-occludin cells. A similar scenario also occurred for E-cadherin distribution, although Raf-1 activation seemed to have decreased the total protein level of E-cadherin (Fig. 4 C), consistent with other reports that E-cadherin is downregulated in transformed epithelial cells (Guilford 1999). Our observation implies that occludin may play a role in the localization of these junctional proteins.
|
·cm2, we examined claudin-1 as a representative of the claudin gene family in our system. Unlike occludin, the majority of claudin-1 protein was Triton X-100–soluble in control Pa-4 cells and only a small percentage was detected in the Triton X-100–insoluble fraction (Fig. 5 A). This suggests that claudin-1 may not be as directly associated with the actin cytoskeleton as occludin. Claudin-1 protein was almost undetectable in Pa-4
Raf-1:ER cells, but recovered to the levels seen in Pa-4-vec cells after the reexpression of occludin (Fig. 5 A). Although there was a decrease of claudin-1 mRNA level in Pa-4
Raf-1:ER cells, surprisingly, Pa-4
Raf-1:ER-occludin cells showed a level of claudin-1 mRNA comparable to that of Pa-4
Raf-1:ER cells (Fig. 5 B) even with the apparent difference in protein levels. To further investigate this observation, we examined the protein levels of occludin and claudin-1 in eight different Pa-4
Raf-1:ER-occludin cell clones. The levels of occludin protein varied significantly among the clones (Fig. 5 C). This is likely due to the location effects of gene insertion during stable transfection. We observed a general correlation between the protein levels of claudin-1 and those of occludin in the Pa-4
Raf-1:ER-occludin clones (Fig. 5 C), but the levels of claudin-1 mRNA among the clones did not change significantly (Fig. 5 D). Therefore, it seems possible that claudin-1 protein was stabilized by the presence of occludin protein in Raf-1–activated Pa-4 cells. Costaining of claudin-1 and occludin revealed some colocalization between these two proteins in Pa-4-vec and Pa-4
Raf-1:ER-occludin cells (Fig. 5 E). Thus, active Raf-1 can completely downregulate the expression of occludin (no detectable mRNA or protein) and decrease the expression of claudin-1, although to a lesser extent compared with occludin (50% decrease of mRNA, 95% decrease of protein). It is possible that the loss of claudin-1 protein in Pa-4
Raf-1:ER cells was due to accelerated protein degradation, implicating a role for occludin in the stabilization of claudin-1. The mechanism of this stabilization is unknown, but may result from protein–protein interactions between occludin and claudin-1 at the TJs. We also noticed that the TEER among the Pa-4
Raf-1:ER-occludin clones did not correlate with the expression levels of occludin or claudin-1 (data not shown), suggesting that occludin and claudins are not the only players in regulating epithelial TJ function. A delicate balance between claudins and occludin levels and other regulatory components of TJs might be necessary to achieve the maximum barrier function.
|
Raf-1:ER Cells in Soft Agarose
Raf-1:ER fusion kinase was sufficient to disrupt TJ function and suppress occludin expression in Pa-4 cells, the kinase activity of
Raf-1:ER can be further induced in the presence of added estradiol. Further induction of Raf-1 activity can greatly increase the ability of Pa-4
Raf-1:ER cells to form colonies in soft agarose plates (Li et al. 1997). We examined the effect of occludin reintroduction on the growth characteristics of Raf-1–activated Pa-4 cells. We found that expression of occludin in Pa-4
Raf-1:ER cells significantly decreased their ability to grow in soft agarose in the absence or presence of estradiol (Fig. 6). Thus, there is a possibility that upregulation of occludin expression could be a potential approach to treat Raf-1–induced epithelial cancers.
|
| Discussion |
|---|
|
|
|---|
Using the chimeric construct
Raf-1:ER in a rat salivary epithelial cell system, we have shown that Raf-1 acts as a signal transducer capable of modulating TJ function. Regulation of occludin expression by Raf-1 may represent a previously unappreciated mechanism in epithelial cell transformation. Although the kinase activity of
Raf-1:ER can be further increased in the presence of added estradiol, the
Raf-1:ER fusion protein has a high level of basal activity (Li et al. 1997). This basal activity is sufficient to induce morphology changes, disruption of TJs, and downregulation of occludin and claudin-1 in Pa-4 cells. That is why most of our studies were carried out in the absence of added estradiol. We have analyzed each of the eight Pa-4
Raf-1:ER-occludin clones obtained through stable transfection. Although these cells showed different levels of occludin and claudin-1 expression, many other properties of these clones that we have studied were similar. For instance, they all maintained high levels of
Raf-1:ER expression, comparable to that of the Pa-4
Raf-1:ER cells. When cultured on semipermeable filter supports, all eight clones grew as monolayers. Immunofluorescence staining also revealed normal distributions of occludin, claudin-1, ZO-1, and actin in these clones. We have also examined the potential effects of added estradiol on Pa-4
Raf-1:ER-occludin cells. Further activation of
Raf-1:ER by estradiol did not change the monolayer phenotype or TEER in any of the Pa-4
Raf-1:ER-occludin clones (data not shown), nor did it change the inability of these cells to grow in soft agarose (Fig. 6). These results are consistent with our other observations, demonstrating that the downregulation of occludin is a downstream cellular event after Raf-1 activation, and reexpression of occludin can reverse some of the phenotypic changes induced by active Raf-1.
Although the MEK-ERK kinase pathway is likely involved in the Raf-1–controlled occludin expression, the details of this regulation remain unresolved. Raf-1 signaling may downregulate occludin at the transcription level or through accelerated protein degradation. In Pa-4
Raf-1:ER-occludin cells, exogenous (human) occludin protein did not appear to be degraded, even though these cells maintained elevated Raf-1 activity. Human occludin protein is highly homologous to rat occludin. If we assume that the occludin degradation machinery in rat cells can recognize human occludin, our data would suggest that the downregulation of occludin by activated Raf-1 was not through accelerated protein degradation. In addition, we have shown that constitutive activation of Raf-1 led to the complete loss of occludin mRNA in Pa-4 cells, clearly demonstrating that changes at the message level were involved. Furthermore, in A549 cells, which have an oncogenic K-ras mutation, inhibition of the Raf-MEK-ERK kinase pathway by a dominant negative Raf-1 mutant or by the MEK inhibitor PD98059 resulted in increased mRNA level of occludin (Li, D., and R.J. Mrsny, manuscript in preparation). Although we can not rule out the possibility that Raf-1 modulates the stability of occludin mRNA, we think it is more likely that Raf-1 regulates occludin expression at the transcription level rather than through degradation.
Raf-1 activation appeared to have broad effects on several other TJ-associated proteins, including claudin-1 and ZO-1. ZO-1 is known to directly interact with occludin (Furuse et al. 1994). A recent study reported that connexin-occludin chimeras containing the ZO-binding domain of occludin localized at epithelial cell TJs and nonepithelial cell contacts (Mitic et al. 1999). In fibroblasts, it has been shown that claudin-1 or claudin-2 recruited occludin to reconstituted TJ strands (Furuse et al., 1998). We observed that in occludin-absent Pa-4
Raf-1:ER cells, the TJ localization of ZO-1 was disrupted and claudin-1 protein was downregulated. The introduction of exogenous occludin into these cells led to the reappearance of ZO-1 and claudin-1 proteins in the TJs. Although the mechanisms underlying these changes are unclear, our study suggests that the TJ targeting interaction among these proteins could be bidirectional. The changes of claudin-1 and ZO-1 in Pa-4
Raf-1:ER cells are likely to have contributed to the disruption of TJs induced by active Raf-1. However, the fact that reintroduction of occludin alone resulted in the return of normal epithelial phenotype and establishment of functional TJs implicates occludin as a more direct target in the signaling cascade originated from Raf-1. Expression of occludin seemed able to increase the protein level of claudin-1, possibly through stabilization, suggesting a direct interaction between occludin and claudins. The recovery of TEER seen in Pa-4
Raf-1:ER-occludin cells could be a direct result of the recovery in claudin-1 protein level, since there is evidence demonstrating TJ structures in the absence of occludin (Saitou et al. 1998). Although the individual and combined functions of occludin and claudins at epithelial TJs are still unclear, we have clearly demonstrated an essential role for occludin in the loss of structure and function of the epithelial TJs in Ras-Raf–driven epithelial transformation.
| Acknowledgments |
|---|
Raf-1:ER cells, and Jeffrey Hooley, Robin Taylor, Wenlu Li, and Deborah Gonzalez for technical assistance.
Submitted: 26 October 1999
Revised: 2 December 1999
Accepted: 19 January 2000
Abbreviations used in this paper: AJ, adherens junction; ERK, extracellular-regulated kinase; MEK, mitogen-activated protein kinase; TEER, transepithelial electrical resistance; TJ, tight junction; ZO-1, zonula occludens 1.
| References |
|---|
|
|
|---|
Bamforth S.D. Kniesel U. Wolburg H. Engelhardt B. Risau W. A dominant mutant of occludin disrupts tight junction structure and function, J. Cell Sci. 112, 1999 1879–1888.[Abstract]
Birchmeier W. Weidner K.M. Behrens J. Molecular mechanisms leading to loss of differentiation and gain of invasivenessin epithelial cells, J. Cell Sci. Suppl. 17, 1993 159–164.
Bruder J.T. Heidecker G. Rapp U.R. Serum-0, TPA-, and Ras-induced expression from AP-1/Ets-driven promoters requires Raf-1 kinase, Genes Dev. 6, 1992 545–556.
Bulkholm I.K. Nesland J.M. Karesen R. Jacobsen U. Borresen-Dale A.L. E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma, J. Pathol. 185, 1998 262–266.[Medline]
Capon D.J. Seeburg P.H. McGrath J.P. Hayflick J.S. Edman U. Levinson A.D. Goeddel D.V. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations, Nature. 304, 1983 507–513.[Medline]
Chen Y. Merzdorf C. Paul D.L. Goodenough D.A. COOH terminus of occludin is required for tight junction barrier function in early Xenopus embryos, J. Cell Biol. 138, 1997 891–899.
Cobb M.H. Hepler J.E. Cheng M. Robbins D. The mitogen-activated protein kinases, ERK1 and ERK2, Semin. Cancer Biol. 5, 1994 261–268.[Medline]
Dudley D.T. Pang L. Decker S.J. Bridges A.J. Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade, Proc. Natl. Acad. Sci. USA. 92, 1995 7686–7689.
Fanning A.S. Mitic L.L. Anderson J.M. Transmembrane proteins in the tight junction barrier, J. Am. Soc. Nephrol. 10, 1999 1337–1345.
Furuse M. Hirase T. Itoh M. Nagafuchi A. Yonemura S. Tsukita S. Tsukita S. Occludina novel integral membrane protein localizing at tight junctions, J. Cell Biol. 123, 1993 1777–1788.
Furuse M. Itoh M. Hirase T. Nagafuchi A. Yonemura S. Tsukita S. Tsukita S. Direct association of occludin with ZO-1 and its possible involvement in the localization at tight junctions, J. Cell Biol. 127, 1994 1617–1626.
Furuse M. Fujita K. Hiiragi T. Fujimoto K. Tsukita S. Claudin-1 and -2novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin, J. Cell Biol. 141, 1998 1539–1550a.
Furuse M. Sasaki H. Fujimoto K. Tsukita S. A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts, J. Cell Biol. 143, 1998 391–401b.
Gopalakrishnan S. Raman N. Atkinson S.J. Marrs J.A. Rho GTPase signaling regulates tight junction assembly and protects tight junctions during ATP depletion, Am. J. Physiol. 275, 1998 C798–C809.[Medline]
Guilford P. E-cadherin downregulation in cancerfuel on the fire?, Mol. Med. Today. 5, 1999 172–177.[Medline]
Jou T.-S. Schneeberger E.E. Nelson W.J. Structural and functional regulation of tight junctions by RhoA and Rac1 small GTPases, J. Cell Biol. 142, 1998 101–115.
Kevil C.G. Payne D.K. Mire E. Alexander J.S. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins, J. Biol. Chem. 273, 1998 15099–15103.
Kojima T. Sawada N. Yamamoto M. Kokai Y. Mori M. Mochizuki Y. Disruption of circumferential actin filament causes disappearance of occludin from the cell borders of rat hepatocytes in primary culture without distinct changes of tight junction strands, Cell Struct. Funct. 24, 1999 11–17.[Medline]
Lacaz-Vieira F. Jaeger M.M. Farshori P. Kachar B. Small synthetic peptides homologous to segments of the first external loop of occludin impair tight junction resealing, J. Membr. Biol. 168, 1999 289–297.[Medline]
Li D. Lin H.H. McMahon M. Ma H. Ann D.K. Oncogenic Raf-1 induces the expression of non-histone chromosomal architectural protein HMGI-C via p44/p42 mitogen-activated protein kinase-dependent pathway in salivary epithelial cells, J. Biol. Chem. 272, 1997 25062–25070.
Madara J.L. Regulation of the movement of solutes across tight junctions, Annu. Rev. Physiol. 60, 1998 143–159.[Medline]
Marshall C.J. Ras effectors, Curr. Opin. Cell Biol. 8, 1996 197–204.[Medline]
McCarthy K.M. Skare I.B. Stankewich M.C. Furuse M. Tsukita S. Rogers R.A. Lynch R.D. Schneeberger E.E. Occludin is a functional component of the tight junction, J. Cell Sci. 109, 1996 2287–2298.[Abstract]
Mitic L.L. Schneeberger E.E. Fanning A.S. Anderson J.M. Connexin-occludin chimeras containing the ZO-binding domain of occludin localize at MDCK tight junctions and NRK cell contacts, J. Cell Biol. 146, 1999 683–693.
Morrison D.K. Cutler R.E. Jr. The complexity of Raf-1 regulation, Curr. Opin. Cell Biol. 9, 1997 174–179.[Medline]
Mullin J.M. Kampherstein J.A. Laughlin K.V. Saladik D.T. Sole A.P. Transepithelial paracellular leakiness induced by chronic phrobol ester exposure correlates with polyp-like foci and redistribution of protein kinase C-alpha, Carcinogenesis. 18, 1997 2339–2345.
Nusrat A. Giry M. Turner J.R. Colgan S.P. Parkos C.A. Carnes D. Lemichez E. Boquet P. Madara J.L. Rho protein regulates tight junctions and perijunctional actin organization in polarized epithelia, Proc. Natl. Acad. Sci. USA. 92, 1995 10629–10633.
Phillips P.G. Tsan M.-F. Direct staining and visualization of endothelial monolayers cultured on synthetic polycarbonate filters, J. Histochem. Cytochem. 36, 1988 551–554.[Abstract]
Quinonez G. Simon G.T. Cellular junctions in a spectrum of human malignant tumors, Ultrastruct. Pathol. 12, 1988 389–405.[Medline]
Ruch R.J. Cesen-Cummings K. Malkinson A.M. Role of gap junctions in lung neoplasia, Exp. Lung Res. 24, 1998 523–539.[Medline]
Saitou M. Ando-Akatsuka Y. Itoh M. Furuse M. Inazawa J. Fujimoto K. Tsukita S. Mammalian occludin in epithelial cellsits expression and subcellular distribution, Eur. J. Cell Biol. 73, 1997 222–231.[Medline]
Saitou M. Fujimoto K. Doi Y. Fujimoto T. Furuse M. Takano H. Noda T. Tsukita S. Occludin-deficient embryonic stem cells can differentiate into polarized epithelial cells bearing tight junctions, J. Cell Biol. 141, 1998 397–408.
Samuels M.L. Weber M.J. Bishop J.M. McMahon M. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human Raf-1 protein kinase, Mol. Cell. Biol. 13, 1993 6241–6252.
Schoenenberger C.A. Zuk A. Kendall D. Matlin K.S. Multilayering and loss of apical polarity in MDCK cells transformed with viral K-ras, J. Cell Biol. 112, 1991 873–889.
Soler A.P. Laughlin K.V. Mullin J.M. Effects of epidermal growth factor versus phorbol ester on kidney epithelial (LLC-PK1) tight junction permeability and cell division, Exp. Cell Res. 207, 1993 398–406.[Medline]
Takeichi M. Cadherins in cancerimplications for invasion and metastasis, Curr. Opin. Cell Biol. 5, 1993 806–811.[Medline]
Tsukita S. Furuse M. Occludin and claudins in tight-junction strandsleading or supporting players?, Trends Cell Biol. 9, 1999 268–273.[Medline]
Vogelstein B. Fearon E.R. Hamilton S.R. Kern S.E. Preisinger A.C. Leppert M. Nakamura Y. White R. Smits A.M.M. Bos J.L. Genetic alterations during colorectal-tumor development, N. Engl. J. Med. 319, 1988 525–532.[Abstract]
Weiss E.E. Kroemker M. Rüdiger A.H. Jockusch B.M. Rüdiger M. Vinculin is part of the cadherin-catenin junctional complexcomplex formation between
-catenin and vinculin, J. Cell Biol. 141, 1998 755–764.
Wolburg H. Neuhaus J. Kniesel U. Krauss B. Schmid E.M. Ocalan M. Farrell C. Risau W. Modulation of tight junction structure in blood-brain barrier endothelial cells. Effects of tissue culture, second messengers and cocultured astrocytes, J. Cell Sci. 107, 1994 1347–1357.[Abstract]
Wong V. Phosphorylation of occludin correlates with occludin localization and function at the tight junction, Am. J. Physiol. 273, 1997 C1859–C1867.[Medline]
Wong V. Gumbiner B.M. A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier, J. Cell Biol. 136, 1997 339–409.
Yuspa S.H. Poirier M.C. Chemical carcinogenesisfrom animal models to molecular models in one decade, Adv. Cancer Res. 50, 1988 25–70.[Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|